{{Rsnum
|rsid=2290573
|Gene=ULK3
|Chromosome=15
|position=74837253
|Orientation=minus
|GMAF=0.2966
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ULK3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 18.6 | 42.5 | 38.9
| HCB | 67.2 | 29.9 | 2.9
| JPT | 61.1 | 34.5 | 4.4
| YRI | 100.0 | 0.0 | 0.0
| ASW | 82.5 | 17.5 | 0.0
| CHB | 67.2 | 29.9 | 2.9
| CHD | 78.0 | 22.0 | 0.0
| GIH | 84.2 | 15.8 | 0.0
| LWK | 95.5 | 4.5 | 0.0
| MEX | 27.6 | 58.6 | 13.8
| MKK | 68.6 | 24.4 | 7.1
| TSI | 31.4 | 54.9 | 13.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs2290573
|Name_s=
|Gene_s=ULK3
|Feature=
|Evidence=PubMed ID:15073101
|Annotation=A significant association between major cytogenetic response (MCyR) and the rs2290573 polymorphism mapped to 15q22.33 was observed in imatinib-treated patients (P = 0.00037, Bonferroni corrected P = 0.025). Individuals with a CC genotype had a MCyR rate of 52% compared with individuals with a CT or TT genotype that had a MCyR rate of 89% (odds ratio, 6.72; 95% confidence interval, 1.51-29.91). CO: The time to progression at 18 months was significantly different between CC and CT/TT genotype using log-rank test or Wilcoxon test (P < 0.03): Six of 29 imatinib-treated patients (21%) with a CC genotype experienced progression events vs five of 84 patients (6%) with a CT or TT genotype. Study size=113
|Drugs=imatinib
|Drug Classes=
|Diseases=Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|Curation Level=Curated
|PharmGKB Accession ID=PA165110623
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2290573
|overall_frequency_n=3847
|overall_frequency_d=9912
|overall_frequency=0.388115
|n_genomes=24
|n_genomes_annotated=0
|n_haplomes=31
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}